Literature DB >> 21985939

Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions.

Claudio Fiorino1, Tiziana Rancati, Gianni Fellin, Vittorio Vavassori, Emanuela Cagna, Valeria Casanova Borca, Giuseppe Girelli, Loris Menegotti, Angelo Filippo Monti, Francesca Tortoreto, Stefania Delle Canne, Riccardo Valdagni.   

Abstract

PURPOSE: To model late fecal incontinence after high-dose prostate cancer radiotherapy (RT) in patients accrued in the AIROPROS (prostate working group of the Italian Association of Radiation Oncology) 0102 trial using different endpoint definitions. METHODS AND MATERIALS: The self-reported questionnaires (before RT, 1 month after RT, and every 6 months for ≤3 years after RT) of 586 patients were available. The peak incontinence (P_INC) and two longitudinal definitions (chronic incontinence [C_INC], defined as the persistence of Grade 1 or greater incontinence after any Grade 2-3 event; and mean incontinence score [M_INC], defined as the average score during the 3-year period after RT) were considered. The correlation between the clinical/dosimetric parameters (including rectal dose-volume histograms) and P_INC (Grade 2 or greater), C_INC, and M_INC of ≥1 were investigated using multivariate logistic analyses. Receiver operating characteristic curves and the area under the curve were used to assess the predictive value of the different multivariate models.
RESULTS: Of the 586 patients, 36 with a Grade 1 or greater incontinence score before RT were not included in the present analysis. Of the 550 included patients, 197 (35.8%) had at least one control with a Grade 1 or greater incontinence score (M_INC >0). Of these 197 patients, 37 (6.7%), 22 (4.0%), and 17 (3.1%) were scored as having P_INC, M_INC ≥1, and C_INC, respectively. On multivariate analysis, Grade 2 or greater acute incontinence was the only predictor of P_INC (odds ratio [OR], 5.9; p = .0009). Grade 3 acute incontinence was predictive of C_INC (OR, 9.4; p = .02), and percentage of the rectal volume receiving >40 Gy of ≥80% was predictive of a M_INC of ≥1 (OR, 3.8; p = .008) and of C_INC (OR, 3.6; p = .03). Previous bowel disease, previous abdominal/pelvic surgery, and the use of antihypertensive (protective factor) correlated highly with both C_INC and M_INC ≥1. The predictive values of the models for C_INC (area under the curve, 0.83) and M_INC ≥1 (area under the curve, 0.73) were greater than the ones for P_INC (area under the curve, 0.62) and more reliable (p = .0001-.0003 against p = .02). Nomograms for the two longitudinal definitions were derived.
CONCLUSIONS: The longitudinal definitions of fecal incontinence (C_INC and M_INC ≥1) were helpful in accounting for both the persistence and the severity of the incontinence. A significant fraction of peak events was consequential to acute incontinence, and a longer duration of symptoms mainly depended on the rectal dose bath (percentage of rectal volume receiving >40 Gy), and pretreatment clinical factors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21985939     DOI: 10.1016/j.ijrobp.2011.06.1953

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  [Radiotherapy in the treatment of advanced and recurrent prostate cancer].

Authors:  D Böhmer
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

Review 2.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

3.  Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer.

Authors:  Andrew Warner; Tom Pickles; Juanita Crook; Andre-Guy Martin; Luis Souhami; Charles Catton; Himu Lukka; George Rodrigues
Journal:  Cureus       Date:  2015-06-11

4.  Multivariate normal tissue complication probability modeling of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.

Authors:  Laura Cella; Vittoria D'Avino; Raffaele Liuzzi; Manuel Conson; Francesca Doria; Adriana Faiella; Filomena Loffredo; Marco Salvatore; Roberto Pacelli
Journal:  Radiat Oncol       Date:  2013-09-23       Impact factor: 3.481

5.  Radiotherapy dose-distribution to the perirectal fat space (PRS) is related to gastrointestinal control-related complications.

Authors:  S L Gulliford; S Ghose; M A Ebert; A Kennedy; J Dowling; J Mitra; D J Joseph; J W Denham
Journal:  Clin Transl Radiat Oncol       Date:  2017-11-06

6.  Nomogram to predict rectal toxicity following prostate cancer radiotherapy.

Authors:  Jean-Bernard Delobel; Khemara Gnep; Juan David Ospina; Véronique Beckendorf; Ciprian Chira; Jian Zhu; Alberto Bossi; Taha Messai; Oscar Acosta; Joël Castelli; Renaud de Crevoisier
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

7.  Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review.

Authors:  Paul Sargos; Mame Daro Faye; Manon Bacci; Stéphane Supiot; Igor Latorzeff; David Azria; Tamim M Niazi; Te Vuong; Véronique Vendrely; Renaud de Crevoisier
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

8.  Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer.

Authors:  Franziska Eckert; Saladin Alloussi; Frank Paulsen; Michael Bamberg; Daniel Zips; Patrick Spillner; Cihan Gani; Ulrich Kramer; Daniela Thorwarth; David Schilling; Arndt-Christian Müller
Journal:  BMC Cancer       Date:  2013-01-22       Impact factor: 4.430

Review 9.  Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis.

Authors:  Hideya Yamazaki; Satoaki Nakamura; Takuya Nishimura; Ken Yoshida; Yasuo Yoshioka; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-09-08       Impact factor: 2.724

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.